Interview with Tapani Sura, General Manager, Astellas Poland
You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother…
Address: Osmanska 14 str.
02-823 Warsaw
Poland
Tel: +48 22 545 11 11
Over the past ten years, Astellas has built a strong position in Urology, Transplantation, and Antibiotics in the Polish market.
Therapy Areas
Transplantation
Urology
Dermatology
Gastroenterology
A Brief History
Astellas Pharma Sp. z o.o. was registered in August 2005 after the merger of the mother companies Yamanouchi and Fujisawa. Its predecessor, Yamanouchi Pharma Sp. z o.o., began its operation in 1999. Before that the business was handled through the Warsaw branch office of Yamanouchi, which was opened in 1992. Fujisawa Branch Office was opened in 2000.
Local Pharmaceutical Market Conditions
After a fast period of growth from 1991 to 2002, the Polish pharmaceutical market has become turbulent because of fast and sometimes unpredictable changes in reimbursement, pricing, and regulations. This has been the case especially when it comes to innovative pharma companies. As a matter of fact, apart from sartans, the last NCEs entered the reimbursement list in 1998. The policy of the Ministry of Health has been and still is to support local industry and generics producers. However, the size of the country (close to 40 million people) still makes it an attractive market.
Astellas Pharma Europe Ltd. is focused on five key therapeutic areas: Transplantation, Urology, Dermatology, Anti-infectives, and Pain Management. In addition, Astellas remains committed to improving the lives of patients with a number of other diseases, including Diabetes and Cardiovascular, CNS, Respiratory, and Gastrointestinal. As an organisation, Astellas is focused on and committed to its R&D programmes and is driven by its philosophy of enriching the lives of people around the world.
You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother…
You joined Eli Lilly Poland in November 2008 as a Marketing Director and you have been leading the affiliate since January 2010. Moreover you are co-chairing the LAWG – Local…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable, approximating 10% year on year. The market size is over five billion Euros which makes…
In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you chose to dedicate your…
Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was…
For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to…
Unlike many pharmaceutical companies, Servier fully operates in all pharma business activities in Poland: research, drug manufacturing and distribution, and health education. Considering your extensive international and regional experience in…
With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market,…
Would you begin by explaining to the readers of Pharmaceutical Executive the importance of the operation in Poland for the company? Indeed Poland because of largest in CEE pharmaceutical market…
Firstly, what attracted you to join the CRO industry with Quintiles over 10 years ago? I had been working for 5 years as a doctor in the internal medicine and…
Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless, Poland has changed and…
The group has significantly invested in Poland. Are you today generally satisfied with the initial and follow up investments from Mediq in the country? The group has been present in…
Stretching across the heart of continental Europe, Poland is a massive bridge that links east and west, old and new, and which epitomizes a changing continent. At one time…
See our Cookie Privacy Policy Here
